Biographies for current and past IMPACT faculty follow below
Beth Israel Deaconess Medical Center
Massachusetts Institute of Technology
Beth Israel Deaconess Medical Center
Massachusetts Institute of Technology
Hiller Life Sciences Strategies, LLC
Massachusetts Institute of Technology
Harvard Medical School
Harvard Medical School
Associate Professor of Electrical Engineering, Electrical Engineering and Computer Science
Associate Professor of Health Sciences and Technology, Harvard-MIT Division of Health Sciences and Technology, MIT
Elfar was previously a member of the Richard M. Lucas Center for Magnetic Resonance Spectroscopy and Imaging at Stanford University. He received his bachelor’s degree summa cum laude in Electrical Engineering from the University of Iceland in 1989, and his MSc and PhD degrees in Electrical Engineering from Stanford University in 1991 and 1995. He was a Fulbright Scholar at Stanford as well as recipient of an award from the American-Scandinavian Foundation.
Joseph V. Bonventre
Chief, Renal Division and Division of Biomedical Engineering, Brigham and Women’s Hospital
President, American Society of Nephrology
Professor, Harvard Medical School
Esther and Harold E. Edgerton Career Development Professor
Assistant Professor, Civil and Environmental Engineering and Mechanical Engineering
Affiliate Faculty of the Institute for Medical Engineering and Science
With a doctoral research focused on the theoretical and numerical study of rotating homogeneous turbulence and a subsequent postdoctoral research focused on the mathematical modeling of infectious diseases and epidemiology, the focus of the Bourouiba Group is to elucidate the poorly understood mechanisms of disease transmission through the lens of fluid dynamics.
Co-founder and COO, Silverstone Biosciences
Before Silverstone, Alan was co-founder and CEO of Obsidio Medical, a research-stage medical device company focused on commercializing a novel interventional biomaterial platform developed at MIT, Harvard Medical School, and Brigham & Women’s Hospital. In parallel, he was also a Harvard Business School Blavatnik Fellow in Life Sciences Entrepreneurship, Harvard’s healthcare-focused entrepreneur-in-residence program.
Prior to the Fellowship, Alan was a Director in the Medtech Practice at Health Advances, a boutique healthcare consulting firm. At Health Advances, he led engagements across almost every major therapeutic area and device category, helping clients from start-ups to leading public medical device companies on a range of commercialization challenges.
Before to graduate school, Alan started his medical device career working in R&D as a biomedical engineer in Medtronic’s cardiac rhythm management business unit. There his experience included new biomaterials development, preclinical and clinical research, and new technology portfolio strategy. His time at Medtronic also included a rotation as a Visiting Scientist at Mayo Clinic in their electrophysiology group.
Alan holds an MBA from Harvard Business School, an SM in Health Sciences and Technology from MIT through the Harvard-MIT Division of Health Sciences and Technology, and a BS in Biomedical Engineering from Johns Hopkins University.
Emery N. Brown
Edward Hood Taplin Professor of Medical Engineering and of Computational Neuroscience, MIT
Warren M. Zapol Professor of Anesthesia, Harvard Medical School, Massachusetts General Hospital
Director, Harvard Sciences and Technology at MIT
Associate Director, Institute for Medical Engineering and Science at MIT
Professor of Health Sciences and Technology, Massachusetts Institute of Technology
Recent technological and experimental advances in the capabilities to record signals from neural systems have led to an unprecedented increase in the types and volume of data collected in neuroscience experiments and hence, in the need for appropriate techniques to analyze them. Therefore, using combinations of likelihood, Bayesian, state space, time-series and point process approaches, a primary focus of the research in Dr. Brown’s laboratory is the development of statistical methods and signal-processing algorithms for neuroscience data analysis.
Dr. Brown practices anesthesiology at Massachusetts General Hospital and holds a joint appointment as Professor of Anesthesia at Harvard Medical School and Professor of Medical Engineering and Computational Neuroscience at MIT. He co-directs the Harvard-MIT Health Sciences and Technology Program. When not studying neural signals of others under the influence of anesthesia, Emery enjoys challenging his own brain by speaking several Romance languages.
Associate Professor of Radiology and Health Sciences and Technology, Harvard Medical School and Beth Israel Deaconess Medical Center.
Deputy Director at Sanofi Pasteur
Director of Education, MIT Energy Initiative
Antje Danielson joined MITEI after eight years at Tufts University, where she directed the Tufts Institute of the Environment and was an assistant professor in the Department of Public Health. Her areas of interest are energy education and carbon capture and storage. She is also interested in research on conditions that underpin interdisciplinary research and collaborations.
Her previous roles include deputy director for sustainability at the Centre for Research into Earth Energy Systems at Durham University in the UK, where she initiated a carbon capture and storage working group. Danielson is a member of the Board of Directors of the National Council for Science and the Environment and has also served as President of the Council for Environmental Deans and Directors. She received teaching awards from Harvard University and an Exceptional Contribution Award from Durham University. In 1999/2000 she co-founded the car-sharing company Zipcar.
Antje holds a PhD in geochemistry from the Freie Universität in Berlin, Germany.
Orthopedic Surgeon, Beth Israel Deaconess Medical Center
Dr. DeAngelis graduated Optimus from Trinity College in Hartford, Connecticut with Honors in General Scholarship and Chemistry. He matriculated at the University of Massachusetts Medical School in Worcester, Massachusetts. Upon graduation, he was elected to Alpha Omega Alpha, the national medical honor society.
Dr. DeAngelis completed his residency in Orthopaedic Surgery at the University of Connecticut. As a Chief Resident, he was the recipient of the Cavazos Award and the Spencer Butterfield Memorial Prize for Excellence in Orthopaedic Trauma.
Upon completion of his residency, Dr. DeAngelis completed the Fellowship is Sports Medicine and Shoulder Surgery at Vanderbilt University in Nashville, Tennessee. Under the guidance of Drs. Kurt P. Spindler, John (Jed) E. Kuhn and Warren R. Dunn, Dr. DeAngelis developed his expertise in the treatment of Sports-Related Injuries and Shoulder Surgery.
Dr. DeAngelis’s research interests include treatment of shoulder and knee conditions, Patient-Reported Outcomes and Evidence Based Medicine in Sports Medicine, as well as tendon to bone healing.
Thomas D. and Virginia W. Cabot Professor, Health Sciences and Technology, MIT
Professor of Medicine, Harvard Medical School Director, Harvard-MIT Biomedical Engineering Center
Senior Physician, Brigham and Women’s Hospital
His research combines his scientific and medical training using controlled drug delivery, growth factor biochemistry, tissue engineering, biomaterials-tissue interactions, and continuum mechanics to examine the mechanisms of tissue repair. His laboratory helped develop and optimize bare metal and drug-eluting stents, and advance endothelial cell and vascular biology, computational modeling of vessel formation, and the homology between endothelial paracrine and angiocrine regulation in cancer and vascular diseases.
As Chief Scientific Advisor of Science: Translational Medicine, he has set the tone for the national debate on translational research and innovation.
Assistant Professor, Wellman Center for Photomedicine at Massachusetts General Hospital
After his graduation, he became a research fellow studying under Johannes de Boer and Tayyaba Hasan at the Wellman Center for Photomedicine. It was here that he developed his interest in imaging cancer therapeutics, building a time-lapse optical coherence tomography system to study tumor treatment response. Selected to join the Wellman and Harvard Medical School faculty in 2010, Prof. Evans’s lab is now growing rapidly in pursuit of new therapeutic options for patients with advanced forms of cancer. Prof. Evans recently received the NIH Director’s New Innovator Award and is a co-recipient of the Dana Farber/Harvard Cancer Center Bridge Project Award.
William J. Febbo
CEO at OptimizeRX
Febbo is also founder of Plexuus, an early stage payment processing platform for medical professionals with Sunshine Act-related activities. Currently, he holds the position of CEO at OptimizeRX and continues to discover, innovate and connect both products and people to meaningful experiences to improve health outcomes. Febbo holds a Bachelor of Arts in International Studies from Dickinson College, in Pennsylvania and serves on the board of The United Nations of Greater Boston, a non-profit focused on building global citizens within inner-city schools in Massachusetts.
Managing Director and Co-Founder of BioVentures Investors
Peter entered the biotechnology industry in December 1981 as a consultant to Biogen. In 1983, following the Biogen IPO, he was hired by Dr. Walter Gilbert to serve as Vice-President, Corporate Communications, where his responsibilities included global investor relations for this leading international biotechnology company during the formative years of the biotechnology industry.
Peter was a co-founder of the Massachusetts Biotechnology Council, serving as Executive Director and was a Director for 12 years. He has also served on the Executive Committee of the Board of Associates of the Whitehead Institute for Biomedical Research, where he co-chaired the Whitehead Circle, and on the Executive Board of the Health Science and Technology Division of Harvard and MIT. As a BVI partner, he has served on the boards of Hospital Care Online (Chm), Sciona (interim CEO), Rcadia Medical Imaging (Chm), Rachiotek (Chm), Cylene Pharmaceuticals, HydroCision, sGC Pharma, BioValve, ActivBiotics, Pintex, CombinatoRx (obs) and Therion (obs). Peter received his B.A. from New York University.
Lisa E. Freed
Massachusetts Institute of Technology
Emily Fisher Landau Professor of Neurology and Neuroscience, Harvard Medical School
Director of Cognative Neurology at Beth Israel Deaconess Medical Center
Co-Founder and Chief Technology Officer at MC10 Inc
Professor of Electrical Engineering & Computer Science and Associate Director of the Computer Science and Artificial Intelligence Laboratory, MIT
Professor Golland received her BSc and Masters in Computer Science from Technion, Israel in 1993 and 1995, and a PhD in Electrical Engineering and Computer Science from MIT in 2001. She joined the faculty in 2003.
J.W. Kieckhefer Professor, Harvard-MIT HST, EECS, RLE, and IMES
Director, Madrid-MIT M+Visión Consortium
Martha’s research interests center on ways to diagnose and treat cartilage degeneration (arthritis). Most recently, she and her research group have pioneered a nondestructive magnetic resonance imaging (MRI) method for assessing cartilage. For the first time, investigators have the opportunity to evaluate therapies based on what is happening to cartilage—rather than pain—and to do so without a surgical biopsy. Her other research interests include connective tissue physiology, imaging, and microfabrication.
Director of the Quantitative Imaging Center, Professor of Radiology, and Section Chief of Musculoskeletal Imaging at Boston University School of Medicine
Dr. Guermazi has been involved as an MRI reader for the past 9 years in several large U.S. studies including the Health Aging and Body Composition (Health ABC) study, the Boston Osteoarthritis Knee study (BOKS), the Multi-center Osteoarthritis STudy (MOST), the Framingham study, Osteoarthritis Initiative (OAI), and other large NIH-funded studies, as well as several Pharmaceutical-sponsored clinical trials. He is author of over 260 peer-reviewed publications and Investigator on numerous research grants related to MRI reading for Osteoarthritis.
Founder of Union Biometrica, Inc.
Dr. Hansen’s career has been almost exclusively in forming businesses and personally conducting commercial science. He is mindful of having been mentored in the 1970s by Louis Kamentsky, who worked in a commercial environment at IBM and is recognized as having created the idea of multi-parameter flow cytometry. Since meeting Lou, Peter has worked to develop multi-parameter flow cytometry, from single cells to multicellular organisms such as c elegans. This commercial life has exposed him to a wonderful variety of experiences. He participated in the first use of antibody therapy in the late 1970’s at MGH by constructing a cellular analysis device that could monitor immunosuppression in transplant patients. Devices like this now count CD4 cells in HIV patients. He began working with plasmonic nanoparticles in the 1980’s and developed commercial products ranging from solution-phase immunoassays to a point-of–care application whereby HIV therapy could be monitored in resource challenged regions. He currently works on extending this technology to understanding the immune response to ovarian cancer. He is guided by defining un-met needs, forming a collaborative, cross-disciplinary, team for solutions and seeking commercial ways to bring the solution to the public, both in the industrialized and developing worlds.
Strategic Consultant and Business Advisor to Start-Up Companies, Hiller Life Sciences Strategies, LLC
Chief, Musculoskeletal Radiology, Beth Israel Deaconess Medical Center
Assistant Professor of Radiology, Harvard Medical School
Director of Radiochemistry, Athinoula A. Martinos Center for Biomedical Imaging
Associate Director, Massachusetts General PET Core, MGH
Associate Professor of Radiology, Harvard Medical School.
He received his undergraduate education at North Carolina State University in Chemistry and Textile Chemistry before moving to the University of California, Berkeley where he completed his Ph.D. During his graduate studies, Dr. Hooker developed new technologies for the construction of biomedical imaging agents using nanometer-sized viruses. Following the completion of his doctoral work in 2007, Dr. Hooker moved to Brookhaven National Laboratory (BNL) in Long Island, NY as a Goldhaber Distinguished Fellow and a Ruth L. Kirschstein NIH Fellow. While at BNL, Dr. Hooker trained under the recent National Medal of Science winner, Joanna Fowler, and worked on the development of new chemical strategies for the synthesis of positron emission tomography imaging agents. For this work, Dr. Hooker was named “Inventor of the Year” in 2009 by Battelle.
In 2007, he was named Goldhaber Distinguished Fellow at Brookhaven National Laboratory and worked with National Medal of Science recipient, Dr. Joanna Fowler, to develop new imaging methods for neuroscience. In 2009, Dr. Hooker moved to Boston to begin is independent career at Harvard. That same year he was awarded the Presidential Early Career Award for Scientists and Engineers by President Obama. The citation from the President noted his strong scientific record and his unique commitment to science mentorship. He has since been recognized by several additional national awards. Prof. Hooker currently serves as an Associate Editor for ACS Chemical Neuroscience, is a core faculty member for the MIT M+Visión Consortium and the Harvard Chemical Biology PhD program.
Cardiology Fellow, Brigham and Women’s Hospital
Co-Founder, Heprotech Inc.
Having trained clinically in cardiology, Dr. King is now focused on improving the care of patients suffering from myocardial infarction and heart failure in two ways: 1) by engineering next generation diagnostics to improve and personalize care, and 2) by developing novel therapeutics that leverage findings from fundamental investigations at the intersection of immunology, cell communication, myocardial injury, and heart failure pathogenesis.
Principal, PNP Research Corp.
Principal, Boston MedTech Advisors
President, Lake Street Enterprise, LLC
Co-Director, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital
Associate Professor of Radiology, Harvard Medical School
Maulik D. Majmudar
Associate Director of the Healthcare Transformation Lab at Massachusetts General Hospital
Chief Medical Advisor and Founding Member of Quanttus
Cardiologist at Veterans Hospital, Boston VA Healthcare System
Instructor at Harvard Medical School
Assistant Dean for Development and Diversity, Harvard Medical School
Associate Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center
Associate Professor in the Department of Epidemiology, Harvard T.H. Chan School of Public Health
Professor of Pathology and Health Sciences and Technology, Harvard Medical School
Vice Chair for Education, Brigham and Women’s Pathology
Associate Director, Health Sciences and Technology, Harvard Medical School
Chief Business Officer, Catabasis Pharmaceuticals
Prior to joining Catabasis, Mr. Modi was senior vice president, global marketing at InterMune, an orphan drug company that was acquired by Roche in 2014. He played a pivotal role in the launch of InterMune’s flagship product, Esbriet. Rick also held roles of increasing responsibilities in corporate strategy, new product planning and sales and marketing at MedImmune (AstraZeneca) and Centocor (Johnson & Johnson). Rick holds an MBA from the Wharton School and a BS in pharmacy from the University of Iowa.
President and CEO of PDS
Asif’s experience also includes executive management roles at AT&T Bell Laboratories, AT&T-NCR and Motorola, where he established and ran successful software, systems and applications businesses. He lived in Europe for several years while working as a general manager in the Internet and Connectivity Solutions Division for Motorola, where he was responsible for establishing and running the software applications business for large telecom operators and enterprises in Europe, the Middle East and Africa (EMEA). In addition to operational experience, Asif has successfully led several national and international mergers and acquisitions.
Asif holds an MSc in electrical engineering and a Ph.D. in computer engineering from Michigan State University. He is a graduate of Harvard Law School’s Program in Negotiation, and studied Leadership at the Center for Creative Leadership, a global provider of training and research on leadership and development. Asif is also an adjunct professor at Michigan State University, where he lectures on entrepreneurship and a wide variety of topics currently challenging the IT industry, and he is an M+Visión Visiting Fellow at MIT.
Massachusetts Institute of Technology (retired)
Lita earned B.S. and M.S. degrees in Chemical Engineering from M.I.T. and an M.S. in Management from M.I.T. as a Sloan Fellow. Prior to joining the M.I.T. TLO, she spent 20 years in industry, primarily in the fields of membrane separations, medical devices, and biotechnology.
Lita has served on many boards including the Association of University Technology as president. She was also on the board of Mass Ventures (MTDC) for 20 years, and is currently on the scientific advisory boards of Partners’ Investment Fund and the Massachusetts Life Sciences Center and is a senior advisor to Omega Funds Limited. She was recently awarded Xconomy’s Lifetime Achievement Award in Biotechnology. In 2009 the UK Government awarded her the honor of “Member of the Order of the British Empire” (MBE) for her work with technology transfer institutions throughout the UK.
Lauren J O’Donnell
Assistant Professor in Radiology at Harvard Medical School
Assistant Professor in Radiation Oncology, Harvard Medical School
Assistant in Biology, Edwin L. Steele Laboratory for Tumor Biology
Vice Chair of Research, Department of Radiology, Beth Israel Deaconess Medical Center
Before coming to BIDMC Dr. Pisano served as the Kenan Professor of Radiology, Vice Dean for Academic Affairs, Director of the Biomedical Research Imaging Center, and Director of the North Carolina Translational and Clinical Studies Institute at the University of North Carolina School of Medicine, and Dean of the College of Medicine, Medical University of South Carolina (MUSC).
Vice President & Head, East Coast Innovation Center, Bayer
Before joining Bayer, Chandra worked at Wyeth (Pfizer) and Bristol-Myers Squibb in various roles including Global Brand Team Leader, Licensing/Business Development, Commercial Strategy, Drug Discovery and Applied Genomics.
Chandra has worked across the pharmaceutical discovery, product development and commercialization spectrum for more than 21 years. He holds an M.B.A from the Columbia Business School, Ph.D. in Genomics/Bioinformatics, M.S. in Medicinal Chemistry and B.S. in Pharmacy.
Raúl San José Estépar
Assistant Professor, Radiology, Harvard Medical School
Research Associate, Brigham and Women’s Hospital
Raúl is focused on the study of lung disease, specifically Chronic Obstructive Pulmonary Disease (COPD), and the development of image-based biomarker for the discovery of genetics determinants and novel clinical associations for disease diagnosis and prognosis. His research interests are focused on medical applications of image analysis. This includes local image structure estimation using tensors analysis, image segmentation, and image registration.
Raúl is co-Director of the Applied Chest Imaging Laboratory and part of the Laboratory of Mathematics in Imaging and the Surgical Planning Laboratory, all of them at Brigham and Women’s Hospital. He is also part of the imaging core of the COPDGene study, a NIH funded study for the discovery of genetic determinants for COPD susceptibility.
VP, Corporate Development and Program Management, Flex-Pharma
Ms. Simonello holds a B.S. degree in biochemistry from Mount Holyoke College, and received her M.S. from Massachusetts College of Pharmacy and Health Sciences.
President at Technology Research Laboratories
Principal Research Scientist and Senior Lecturer in the Department of Mechanical Engineering, MIT
Dr Socrate’s research interests focus on identifying and modeling the mechanisms governing the deformation response of materials, including polymers, gels, biological tissue and fabrics, relating their macroscopic behavior to their underlying structure. Her current research efforts include: experimental and computational studies of the response of brain tissue; development of in-vitro systems to investigate brain cell response to pressure (shock) waves; investigation of appropriate resuscitation strategies during the early management of patients with TBI; experimental investigation and modeling of the dynamic response of high-performance fabrics; biomechanics of pregnancy and preterm delivery. During her tenure at MIT, Dr. Socrate has mentored 7 S.M, 11 Ph.D students and 4 postdoctoral associates. She is the author of over 50 publications in peer-reviewed journals and over 100 publications in conference proceedings.
Nancy R. Steele
Vice President, External Ventures, Pfizer Inc
Nancy Steele has worked at Pfizer for over 30 years in a range of leadership roles, including Corporate Strategy, Business Development and Organization Development. Her contributions helped to expand the product portfolio, forging business development collaborations in adjacent areas including diagnostics and digital health technologies. Earlier in her career, Nancy was the founder of a health services company, Pfizer Health Solutions (PHS), a subsidiary delivering patient care management and clinical decision support to payers and providers in the management of chronic conditions, including diabetes, COPD, depression, asthma and hyper- tension.
Prior to Pfizer, Nancy’s experience included clinical research in a psychiatric hospital, marketing of biomedical devices, leadership development at IBM, and serving as a ward psychologist in a mental health facility.
Nancy holds a BA in Psychology from the New School for Social Research and a MA in Organizational Psychology from Columbia University.
Professor at EECS, RLE, Harvard-MIT HST, and IMES
Global Product Lifecycle Leader, OvaScience
Most recently she has held a variety of business development, strategy and marketing roles at Philips Healthcare which has included work in: imaging diagnostics, healthcare software development, new business model innovation, lifecycle and service strategy, and new solution / product introduction. While at Philips, Ms Taylor spent 5 years in the Netherlands developing and globally launching new customer-centric service solutions. Her expertise includes segmentation and positioning, pricing and end-end product strategy.
Post MBA, Ms Taylor was a strategy consultant for Mercer Management Consulting before moving to Boston and joining Sensitech, a venture-back firm, that provided supply chain solutions for the pharmaceutical industry.
Ms Taylor holds an MBA in marketing and strategy from the Kellogg Graduate School in Evanston, IL and a BS in biology from the University of Michigan in Ann Arbor, MI. She lives outside of Boston with her family and quirky dog.
Director of Business Development and Strategy, Neon Therapeutics
Ronald G. Tompkins
Sumner M. Redstone Professor of Surgery, Harvard Medical School
Division Chief, Surgery, Science and Bioengineering, Divison of Surgery, MGH
Founding Director, The Institute for Bioengineering and Biotechnology, MGH
Founding Director, Center for Engineering in Medicine, MGH
Ron serves as the principal investigator of the first-in-the-nation P50 award (P50-GM21700 in 1974) from the National Institute of General Medical Sciences and its associated NIGMS T32 Burn Research Training Grant (T32-GM07035 in 1975) for postdoctoral training in burn and trauma research. Ron’s research as the principal investigator of the “Inflammation and the Host Response to Injury” program (U54-GM062119) – the largest award ever received by MGH and 10th largest of the extramural NIH grants – has developed the clinical infrastructure to study critically ill trauma populations, as well as the technological and bioinformatics skills to isolate leukocyte populations and probe the transcriptome as it responds to severe injury. The development of clinical treatment protocols by consensus of the trauma and burn centers participating in this “Glue Grant” program led to improvements in survival, reduction in morbidity for injured patients, and established benchmarks for care in the fields of burns and trauma.
Innovations developed within the Division have found many applications, including detection of trisomy within the first trimester of pregnancy to replace amniocentesis, capture of circulating tumor cells to diagnose and treat cancer, and suggest subsequent treatments; and count of CD4+ cells in the blood at points of care such as Sub-Saharan Africa and Southeast Asia to enable rationale treatment with antiviral drugs.
Helen Andrus Benedict Professor of Surgery (Biomedical Engineering) and Health Sciences and Technology, MIT
Professor Toner obtained his undergraduate degree in Mechanical Engineering at the Istanbul Technical University in 1983, and his master’s degree and doctorate in Mechanical Engineering and Medical Engineering at MIT in 1989. Toner worked on his doctorate under Prof. Ernest Cravalho who was one of the first engineering scientists to work on cryobiology and is still a professor of mechanical engineering at MIT. Dr. Toner’s early work focused on understanding cellular injuries during cryopreservation and finding optimum strategies for cell preservation. His later works include microfluidics, Bio-sensing and dry preservation of mammalian cells.
Prof. Toner currently serves as the Associate Director of the Center for Engineering in Medicine(CEM) located at the Massachusetts General Hospital and Shriners Hospital for Children, as well as the Director of the CEM-affiliated BioMEMS Resource Center. The labs have produced several researchers and continues to train post-doctoral fellows and graduate students from MIT and Harvard University.
Scientific Founder, President, and CEO of Concert Pharmaceuticals
Prior to Concert, Roger worked in venture-backed start-up and major pharmaceutical companies including Merck and Vertex Pharmaceuticals, in the latter case as a founding scientist and most recently as Vice President of Drug Discovery. Roger has overseen the discovery of five drugs approved in the US for the treatment of cystic fibrosis, hepatitis C, and HIV infection. He is co-inventor of two marketed HIV drugs and has been issued over 100 US patents. He has authored or co-authored over 100 scientific papers, book chapters, and abstracts.
Roger received a BA in Chemistry from Reed College in Portland, OR, and a PhD in Pharmaceutical Chemistry from UW-Madison. He serves as a biotech and venture capital scientific advisor, is a faculty mentor for MIT’s IMPACT program, and is a member of the UW-Madison School of Pharmacy’s Board of Visitors.
Jessica Dawn Tytell
Executive Director, Biological Design Center, Boston University
Dr. Tytell earned her Ph.D. in Biology from MIT and completed her postdoctoral fellowship at Children’s Hospital Boston, investigating how cells interact with their physical environment. She founded the Boston Area Mitosis Meiosis group to foster collaboration and promote innovation between Boston-area researchers, and has worked with the Association for Women in Science for more than 10 years.
Assistant Professor, Harvard Medical School
Massachusetts General Hospital Wellman Center for Photomedicine
Their laboratory focuses on the development and translation of optical technologies into either patient care or biological studies. In the clinic, they are developing coherent optical imaging platforms that can be deployed endoscopically to diagnosis and guide the treatment of disease. In the biological laboratory, they are developing these imaging technologies into tools that provide new insight into disease processes and therapeutic responses. The Lab’s methodology combines a core focus on optical technologies with broad-based engineering and cross-disciplinary collaboration.
Associate Professor in Radiology, Harvard Medical School
Associate Biophysicist, Massachusetts General Hospital
Director, MGH NMR Core, Martinos Center
Chief Medical Officer of Flex-Pharma
Prior to joining Flex Pharma, Dr. Wessel was an independent consultant to several biotechnology and large pharmaceutical companies, including Concert Pharmaceuticals, Inc., Alkermes plc, Sanofi SA and Novartis AG. Previously, Dr. Wessel was the Chief Medical Officer of Acorda Therapeutics, Inc. from November 2008 until September 2011. Between March 2002 and October 2008, Dr. Wessel was employed in various leadership positions at Sepracor, Inc., including Senior Vice President of Clinical Research. Before joining Sepracor, Dr. Wessel worked on several CNS projects at Janssen Pharmaceuticals in Europe and the U.S. Before working in the pharmaceutical industry, Dr. Wessel held several academic and research positions.
Dr. Wessel received his M.D. from the University of Munich School of Medicine and completed his Ph.D. in experimental neurobiology at the Max-Planck-Institute for Psychiatry in Martinsried, Germany. He completed his residency in neurology at New York Hospital and Memorial Sloan-Kettering Cancer Center (Cornell University Medical Center).
John (Jack) Wixted
Orthopaedic surgeon at Beth Israel Deaconess Medical Center